arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BIOCRYST PHARMACEUTICALS INC

BCRX
$9.37 ▲ +0.07 (+0.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
62
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

BIOCRYST PHARMACEUTICALS INC demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $2.3B
Dividend Yield
Revenue Growth 7.5%
Op. Margin -448.6%
ROIC 442.9%
FCF / Share $-0.26
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.71
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$156.41M
↑ +7.5%
Net Income Profit after all expenses
$-721.81M
↓ -393.6%
Operating Margin Operating profit as % of sales
-448.6%
↓ -2516.2% 93th
FCF / Share Free cash flow per share
$-0.26
↓ -93.6%
Long-Term Debt Long-term obligations
$395.20M
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
93
Returns
1
Financial Health
91
Cash Quality
76

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters